Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

122.25 +0.39 (+0.32%)

Streaming Delayed Price Updated: 3:17 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Is Merck Stock a Buy? ↗

September 29, 2024

There is mounting pressure on the company's most prized franchise.

Via The Motley Fool

Evaxion Biotech Partners With Merck To Expand Vaccine Development ↗

September 26, 2024

Evaxion Biotech enters an expanded collaboration with Merck, granting an option to license preclinical vaccine candidates. The deal includes $3.2 million upfront and potential earnings up to $592...

Via Benzinga

This Is What Whales Are Betting On Merck & Co ↗

September 25, 2024

Via Benzinga

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients ↗

September 25, 2024

The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers.

Via Benzinga

Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years ↗

September 25, 2024

Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and...

Via Benzinga

Merck & Co Unusual Options Activity For September 23 ↗

September 23, 2024

Via Benzinga

Exploring NYSE:MRK's dividend characteristics. ↗

September 20, 2024

Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK).

Via Chartmill

Behind the Scenes of Merck & Co's Latest Options Trends ↗

September 18, 2024

Via Benzinga

NYSE:MRK: good value for what you're paying. ↗

September 18, 2024

MERCK & CO. INC. (NYSE:MRK) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study ↗

September 25, 2024

Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve overall survival compared to standard treatments, though safety remained...

Via Benzinga

Pfizer Advances On Its Cancer Journey ↗

September 20, 2024

On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024...

Via Benzinga

Is It Too Late to Buy ServiceNow Stock? ↗

September 20, 2024

The stock is up nearly 60% since the beginning of the year.

Via The Motley Fool

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer ↗

September 18, 2024

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line treatment of advanced or metastatic malignant pleural mesothelioma.

Via Benzinga

Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry ↗

September 17, 2024

Via Benzinga

A Closer Look at 8 Analyst Recommendations For Merck & Co ↗

September 16, 2024

Via Benzinga

Where Will Merck Stock Be in 5 Years? ↗

September 14, 2024

This drugmaker faces a key test in the next several years.

Via The Motley Fool

This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous. ↗

September 18, 2024

There's a lot of hope for ivonescimab, but are investors being a bit too bullish?

Via The Motley Fool

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030 ↗

September 18, 2024

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

Via The Motley Fool

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery ↗

September 17, 2024

BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.

Via Investor's Business Daily

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study ↗

September 17, 2024

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival...

Via Benzinga

NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges ↗

September 16, 2024

NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disease control rate in metastatic melanoma patients resistant to prior PD-1...

Via Benzinga

Merck & Co Unusual Options Activity ↗

September 13, 2024

Via Benzinga

Merck Scores Two Key Victories With Keytruda In Women's Cancers ↗

September 15, 2024

The company also unveiled 10-year test results for Keytruda in advanced melanoma patients.

Via Investor's Business Daily

Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target ↗

September 13, 2024

Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight near-term challenges, lowered price targets, and a delayed breakeven to 2028,...

Via Benzinga

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Via Talk Markets

Topics ETFs

Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day ↗

September 13, 2024

The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday.

Via Investor's Business Daily

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale ↗

September 12, 2024

The company is adding onto its success outperforming Merck's top drug in lung cancer patients.

Via Investor's Business Daily

Is Summit Therapeutics a Buy Now? ↗

September 10, 2024

The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.

Via The Motley Fool

Why Summit Therapeutics Rocketed Over 60% Today ↗

September 09, 2024

The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.

Via The Motley Fool

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Merck & Co (NY:MRK)

Headline News about Merck & Co

Starting at $3.75/week.

Subscribe Today